Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

A Hole in the Heart Journal of Thoracic Oncology

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Inflammatory Myofibroblastic Tumor of the Left Main Stem Bronchus

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Pharmacogenetic Analysis of BR

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

MET Mutation Associated with Responsiveness to Crizotinib

Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.

Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc, Thomas K.

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer Peter M. Ellis, MBBS,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Frank Detterbeck, MD Journal of Thoracic Oncology

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Surgical Treatment of a Giant Symptomatic Cardiac Lipoma

Prevention and Management of Bone Metastases in Lung Cancer: A Review

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer Thomas John, MBBS, PhD, Naoki.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

“The Best-Laid Plans … Often go Awry …”

A Hole in the Heart Journal of Thoracic Oncology

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Nasion Swelling as the Presenting Symptom of Lung Adenocarcinoma

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

MTP13-01: Indications and limitations of bronchoscopy

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas Bin Gao, BS, Yihua Sun, MD, Junhua Zhang, MD, Yan Ren, PhD, Rong Fang, BS,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

European Lung Cancer Conference (ELCC) 2016 Organisation

Metastatic Lung Cancer to the Pancreas

S-1 Treatment for Chemorefractory Thymic Carcinoma

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

David Garfield, MD Journal of Thoracic Oncology

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma Akira Sakurada, MD, Humberto Lara-Guerra, MD, Ni Liu, MSc, Frances A. Shepherd, MD, Ming-Sound Tsao, MD Journal of Thoracic Oncology Volume 3, Issue 5, Pages 527-529 (May 2008) DOI: 10.1097/JTO.0b013e318168be93 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 The histopathology, direct sequencing, and fragment length analysis results on three different paraffin blocks of case P163. Left pictures show histology (H&E staining) of paraffin sections from blocks P163#1(A), #2(D), and #3(G). All sections showed similar morphology. Deletion was demonstrated in P163#2(E) and P163#3(H) as indicated by black arrows but not in P163#1(B). The 15-nt deletion was also demonstrated by LFA in P163#2(F) and P163#3(I) as indicated by red arrows, but not in P163#1(C). Journal of Thoracic Oncology 2008 3, 527-529DOI: (10.1097/JTO.0b013e318168be93) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions